These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 10681359

  • 21. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.
    Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, Rinaldi MG, Stevens DA, Graybill JR.
    Medicine (Baltimore); 2000 Jul; 79(4):250-60. PubMed ID: 10941354
    [Abstract] [Full Text] [Related]

  • 22. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
    Warn PA, Morrissey G, Morrissey J, Denning DW.
    J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
    [Abstract] [Full Text] [Related]

  • 23. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression.
    Graybill JR, Bocanegra R, Najvar LK, Loebenberg D, Luther MF.
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2467-73. PubMed ID: 9756743
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
    Paterson PJ, Seaton S, Prentice HG, Kibbler CC.
    J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Efficacy of fluconazole in experimental invasive aspergillosis.
    Patterson TF, Miniter P, Andriole VT.
    Rev Infect Dis; 1990 Nov; 12 Suppl 3():S281-5. PubMed ID: 2184506
    [Abstract] [Full Text] [Related]

  • 29. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis.
    Roberts J, Schock K, Marino S, Andriole VT.
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3381-8. PubMed ID: 11083644
    [Abstract] [Full Text] [Related]

  • 30. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice.
    Connolly P, Wheat J, Schnizlein-Bick C, Durkin M, Kohler S, Smedema M, Goldberg J, Brizendine E, Loebenberg D.
    Antimicrob Agents Chemother; 1999 Feb; 43(2):322-8. PubMed ID: 9925526
    [Abstract] [Full Text] [Related]

  • 31. Itraconazole--perspectives for the management of invasive aspergillosis.
    Groll AH.
    Mycoses; 2002 Feb; 45 Suppl 3():48-55. PubMed ID: 12690972
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Pharmacodynamics and pharmacokinetics of antifungals for treatment of invasive aspergillosis.
    Bellmann R.
    Curr Pharm Des; 2013 Feb; 19(20):3629-47. PubMed ID: 23278532
    [Abstract] [Full Text] [Related]

  • 34. Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis.
    Moosa MY, Alangaden GJ, Manavathu E, Chandrasekar PH.
    J Antimicrob Chemother; 2002 Jan; 49(1):209-13. PubMed ID: 11751792
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis.
    Kirkpatrick WR, Perea S, Coco BJ, Patterson TF.
    J Antimicrob Chemother; 2002 Feb; 49(2):353-7. PubMed ID: 11815579
    [Abstract] [Full Text] [Related]

  • 37. Invasive aspergillosis caused by Aspergillus terreus in a non-immunosuppressed patient.
    Verghese S, Arjundas D, Shakoor TP, Padmaja P, Elizabeth SJ, Maria CF.
    J Assoc Physicians India; 2002 Aug; 50():1086-8. PubMed ID: 12421042
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
    Perfect JR, Cox GM, Dodge RK, Schell WA.
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1910-3. PubMed ID: 8843302
    [Abstract] [Full Text] [Related]

  • 40. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
    Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, Rubin RH, Wingard JR, DePauw B, Schlamm HT, Troke P, Bennett JE, European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG), Pfizer Global Aspergillus Study Group.
    Clin Infect Dis; 2005 Nov 15; 41(10):1448-52. PubMed ID: 16231256
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.